Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

to the identification of a dosing regimen that is expected to result in optimal TCR modulation, enhanced tolerability, no immunogenicity, beneficial clinical activity, and an improved safety profile. This regimen is currently being evaluated in the ongoing multinational Phase 3 clinical trial, DEFEND, which is characterizing the safety and efficacy of otelixizumab, a novel anti-CD3 monoclonal antibody, in new onset autoimmune type 1 diabetes patients.

About the DEFEND Study

DEFEND is a randomized, placebo-controlled Phase 3 trial intended to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers throughout Europe and North America. The trial is designed to evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will preserve beta cell function as measured by c-peptide, a surrogate measure of beta cell function. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. For information about DEFEND, please visit: www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.


'/>"/>
SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 The ... Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) ... The global market for Eubiotics was valued at USD 4.62 ... Billion by 2020, at a CAGR of 7.4% from 2015 ...
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... for Cancer Research and Education (FCRE) announced today that,prostate ... on new treatments for prostate cancer at Westminster at ... PM., "With the recent press around prostate cancer ... "The good news is there are many,things people can ...
... new Mayo,Clinic study found that regular physical exercise ... of the brain that affects nerve cells,involved in ... the,American Academy of Neurology Annual Meeting in Chicago ... impairment can function reasonably well,in everyday activities, but ...
Cached Medicine Technology:Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles 'Snuffy' Myers Announces Vitamin D Clinical Trials 2Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 2
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com ... dating sites . According to the listings, MillionaireMatch.com bags the top ... , A spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed ...
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... Yisrayl ... a new publication and pleads for swift actions to be taken in order ... unnatural disasters. , Yisrayl says scientists have yet to understand fully the real ...
(Date:8/28/2015)... ... August 28, 2015 , ... Super-Sod launched their new website ... The most notable change is the responsive web design. Website users will now have ... easily submit quote requests for sod, sign-up for the monthly turf-tips email, and find ...
(Date:8/28/2015)... ... ... Santa Rosa was recently recognized, for the fourth consecutive year, as one ... “2015 Midterm Performance Review: Software & Services”, Santa Rosa achieved the highest rating of ... KLAS are directly related to our company culture.” said Richard Helppie, chairman and chief ...
(Date:8/27/2015)... ... August 28, 2015 , ... Shortening the school ... performance in mathematics, according to researchers at Georgia State University and Montana State ... July, analyzed the impact of a four-day school week on student achievement by ...
Breaking Medicine News(10 mins):Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 3
... Va., April 10 - The National,Community Pharmacists Association ... incumbent representing North Carolina,s 3rd,Congressional District, who has ... community pharmacies and their patients. He is facing ... on May 6. Bruce,Roberts, RPh, executive vice president ...
... examination by independent ... auditors, ... auditors as a result of its first Type,II SAS 70 compliance audit. ... a major U.S. accounting firm over a,period of five months. The audit ...
... , The removal through endoscopy of tumours that ... avoid complete extirpation of this part of the digestive ... of Navarra for the last three years, was presented ... the Digestive System, organized by the Digestive System Service ...
... researchers have identified a mating mechanism that possibly,could ... the,viruses that cause dengue fever, second only to ... tropical world. , Specifically, they have discovered 63 ... during mating and are thought,briefly to change the ...
... 10 The Deafness Research,Foundation (DRF) is hosting a ... achievements in hearing health and research,and to inaugurate the ... Foundation is one of the largest and oldest,hearing research ... a,lifetime of hearing health possible for all people through ...
... significantly reduce total cost of ... ... announced that Chicago-based uBid, which helps sellers and,manufacturers liquidate excess inventory, ... replace both its Oracle,E-Business Suite enterprise resource planning system and its ...
Cached Medicine News:Health News:GHX Achieves SAS 70 Compliance 2Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 2Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 3Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 4Health News:Mosquito mating mechanism could lead to new attack on dengue and yellow fever 2Health News:Deafness Research Foundation 50th Anniversary Celebration 2Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 2Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 3Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 4Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 5Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: